Statement: the primary trial and the secondary trial share at least one drug in their chemotherapy regiment.
Primary_evidence: INTERVENTION 1:    ChemoRT   Concurrent Carboplatin and Radiotherapy   Carboplatin: IV, weekly for 6 weeks, AUC of 2.0   3D-RT or IMRT: From week 2 to week 4 in the 6-week Carboplatin treatment: Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy
Secondary_evidence: INTERVENTION 1:    High-dose Chemotherapy   Carboplatin + Cyclophosphamide + Thiotepa   Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.   Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.   Stem Cell Transplant : Stem Cell Transplant on Day 0.   Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.